Evidence map›Paper›PMID 29399967›Full record

ArticleThe FEBS journal2018

Exosomes derived from B16F0 melanoma cells alter the transcriptome of cytotoxic T cells that impacts mitochondrial respiration.

Cassidy L Bland, Christina N Byrne-Hoffman, Audry Fernandez, Stephanie L Rellick, Wentao Deng, David J Klinke

Abstract read
In one paragraph

Article in The FEBS journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Exosome Mediated Cancer Therapeutic Approach:Present Status and Future Prospectives.Asian Pacific journal of cancer prevention : APJCP · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Exosomes-mediated tumor treatment: One body plays multiple roles.Asian journal of pharmaceutical sciences · 2022
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Cassidy L BlandDepartment of Chemical and Biomedical Engineering and WVU Cancer Institute, West Virginia University, Morgantown, WV, USA.
Christina N Byrne-HoffmanDepartment of Pharmaceutical Sciences, West Virginia University, Morgantown, WV, USA.
Audry FernandezDepartment of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.
Stephanie L RellickDepartment of Physiology and Pharmacology, West Virginia University, Morgantown, WV, USA.
Wentao DengDepartment of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.
David J KlinkeDepartment of Chemical and Biomedical Engineering and WVU Cancer Institute, West Virginia University, Morgantown, WV, USA.ORCID 0000-0003-3299-4938
West Virginia University · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI GARY O RANKIN · 2012 to 2026
$61.1M
West Virginia Flow Cytometry Core FacilityP30GM103488 · NIGMS · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2012 to 2016
$4.8M
Integrative systems approach to identify local oncogenic modulation of the IL12 axisR01CA193473 · NCI · WEST VIRGINIA UNIVERSITY · PI KLINKE, DAVID JOHN · 2016 to 2020
$1.7M
COBRE FOR SIGNAL TRANSDUCTION AND CANCER PHASE IIIP30RR032138 · NCRR · WEST VIRGINIA UNIVERSITY · PI GIBSON, LAURA F. · 2011 to 2011
$1.1M
Special Becton Dickinson Fortessa Flow CytometerS10OD016165 · OD · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2013 to 2013
$384k
NCI NIH HHS R01 CA193473NCRR NIH HHS P30 RR032138NIGMS NIH HHS P20 GM103434NIGMS NIH HHS P30 GM103488NIGMS NIH HHS U54 GM104942NIH HHS S10 OD016165
6 · The paper itself

Abstract

While recent clinical studies demonstrate the promise of cancer immunotherapy, a barrier for broadening the clinical benefit is identifying how tumors locally suppress cytotoxic immunity. As an emerging mode of intercellular communication, exosomes secreted by malignant cells can deliver a complex payload of coding and noncoding RNA to cells within the tumor microenvironment. Here, we quantified the RNA payload within tumor-derived exosomes and the resulting dynamic transcriptomic response to cytotoxic T cells upon exosome delivery to better understand how tumor-derived exosomes can alter immune cell function. Exosomes derived from B16F0 melanoma cells were enriched for a subset of coding and noncoding RNAs that did not reflect the abundance in the parental cell. Upon exosome delivery, RNAseq revealed the dynamic changes in the transcriptome of CTLL2 cytotoxic T cells. In analyzing transiently coexpressed gene clusters, pathway enrichment suggested that the B16F0 exosomal payload altered mitochondrial respiration, which was confirmed independently, and upregulated genes associated with the Notch signaling pathway. Interestingly, exosomal miRNA appeared to have no systematic effect on downregulating target mRNA levels. DATABASES: Gene expression data are available in the GEO database under the accession SuperSeries number GSE102951.

Indexed as

TranscriptomeAnimalsCell Line, TumorExosomesGene Expression Regulation, NeoplasticMelanomaMiceMicroRNAsMitochondriaOxygen ConsumptionRNA, MessengerSignal TransductionT-Lymphocytes, CytotoxicTumor MicroenvironmentMicroRNAsRNA, Messengercell-mediated immunityexosomesheterotypic cell communicationRNA sequencingtumor microenvironment

Identifiers

PMID29399967
PMCPMC6457271
OpenAlexW2792023347

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.